addressing the issue of resistance to tkis in cml
Published 1 year ago • 65 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
3:18
granulocytes & t-cells as biomarkers for relapse in cml following discontinuation of tkis
-
5:26
real-world analysis: molecular monitoring and adherence patterns to tkis in older patients with cml
-
2:14
addressing the high rate of disease relapse following allosct in patients with aml
-
1:17
ponatinib versus ascimininib in the third-line treatment of cml
-
4:33
optimizing discontinuation of tyrosine kinase inhibitor treatment for chronic myeloid leukemia
-
39:26
rsm covid-19 series | episode 47: treating severe cases and the inflammatory response
-
10:01
2024年 flt3-itd基因突變急性血癌最新治療與成功經驗分享
-
58:31
stanford cancer institute breakthroughs in cancer: luis diaz, md
-
2:27
ascembl: asciminib versus bosutinib in third-line treatment of cp-cml
-
8:57
outcomes of sct in t-all and t-lbl
-
1:46
towards a personalized treatment approach for scd
-
1:12
addressing the issue of cost of treatment in cll
-
1:25
therapeutic targeting of splicing factor mutations in myeloid malignancies
-
1:51
treatment schedule for ruxolitinib in patients with mpns and how to assess response
-
6:35
measuring residual disease in granulocytes to predict relapse after therapy cessation in cml
-
1:13
the allg cml13 ascend-cml study: high major molecular responses with asciminib treatment for cp-cml
-
2:42
the value of circulating tumor cells for the staging of patients with ndmm
-
1:20
regulation of tetraspanin cd63 in cml progression: single-cell analysis of asymmetric hsc division
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
0:47
overview of the phase iii enhance trial schema
-
1:19
barriers to accessing reni-cel for the treatment of scd
-
1:05
personalized therapy in leukemia: a case study